1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Nabriva Therapeutics Acquires Zavante Therapeutics

M&A Deal Summary

Nabriva Therapeutics Acquires Zavante Therapeutics

On July 24, 2018, Nabriva Therapeutics acquired life science company Zavante Therapeutics

Acquisition Highlights
  • This is Nabriva Therapeutics’ 1st transaction in the Life Science sector.
  • This is Nabriva Therapeutics’ 1st transaction in the United States.
  • This is Nabriva Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2018-07-24
Target Zavante Therapeutics
Sector Life Science
Buyer(s) Nabriva Therapeutics
Deal Type Add-on Acquisition
Advisor(s) BofA Securities (Financial)
Latham & Watkins (Legal)

Target

Zavante Therapeutics

San Diego, California, United States
Zavante Therapeutics, Inc. is a developer of a novel medicines for the treatment of diseases that affect patients in the hospital setting. Zavante Therapeutics was founded in 2013 and is based in San Diego, California.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Nabriva Therapeutics

Dublin, Ireland
Category Company
Founded 2005
Sector Life Science
Employees39
Revenue 36M USD (2022)
DESCRIPTION

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in research and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics was founded in 2005 and is based in Dublin, Ireland.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal